{
  "prompt": {
    "prompt": "Original Transcript:\nDictation: Clinical Interaction – Twin Pregnancy with Obstetric Cholestasis\n Patient Details:\nName: [Fictional Name] Sarah Ahmed\n\n\nAge: 32\n\n\nBMI: 24.7 (weight 68 kg, height 1.66 m)\n\n\nGravida: 2, Para: 1 (previous spontaneous vaginal delivery at term)\n\n\nCurrent Gestation: 32+2 weeks (DCDA twins confirmed on early scan)\n\n\nBooking bloods and anomaly scans: Unremarkable\n\n\nHistory of Presenting Complaint:\n Ms. Ahmed presents with a 10-day history of worsening pruritus, predominantly affecting her palms and soles, with associated sleep disturbance. She denies any new skin rashes or recent medication changes. No history of abdominal pain, dark urine, or pale stools. Fetal movements are reported as normal for both twins. No vaginal bleeding or uterine tightenings.\nRelevant Obstetric History:\nPrevious pregnancy uncomplicated; term vaginal delivery.\n\n\nNo history of intrahepatic cholestasis in prior pregnancy.\n\n\nNo history of preterm labour or hypertensive disorders.\n\n\nRelevant Medical History:\nMild childhood asthma (not on regular treatment).\n\n\nNo known liver or gallbladder disease.\n\n\nMedications & Allergies:\nCurrently taking ferrous fumarate and pregnancy multivitamin.\n\n\nNo known drug allergies.\n\n\nSocial History:\nLives with husband and toddler son.\n\n\nNon-smoker; does not consume alcohol.\n\n\nWorks part-time as a dental nurse; currently on maternity leave.\n\n\nExamination Findings:\nGeneral: Alert and well, no jaundice noted.\n\n\nAbdomen: Uterus consistent with gestational age; fundal height 33 cm.\n\n\nTwins in cephalic/cephalic lie; both heartbeats auscultated and regular.\n\n\nNo uterine tenderness or signs of labour.\n\n\nNo peripheral oedema; BP 118/74 mmHg.\n\n\nNotable Omissions (for testing purposes):\nNo documented baseline bile acid levels from booking bloods.\n\n\nNo record of fetal growth scan within the last 2 weeks.\n\n\nNo documentation of CTG to assess current fetal wellbeing.\n\n\nImpression:\n Twin pregnancy (DCDA) complicated by suspected obstetric cholestasis. Pruritus in the absence of rash raises concern for intrahepatic cholestasis of pregnancy (ICP), particularly given gestation and multifetal pregnancy.\nManagement Plan:\nInvestigations:\n\n\nSerum bile acids and liver function tests (LFTs) urgently.\n\n\nFasting bile acids if initial results are borderline.\n\n\nFull blood count and clotting screen (due to potential risk of coagulopathy).\n\n\nCTG to assess fetal wellbeing.\n\n\nGrowth scan and umbilical artery Dopplers if not done in past 2 weeks.\n\n\nMedical Management:\n\n\nStart ursodeoxycholic acid 500 mg BID while awaiting results.\n\n\nConsider chlorphenamine for symptomatic relief of itching.\n\n\nOngoing Care and Delivery Planning:\n\n\nWeekly bile acids and LFTs.\n\n\nIncrease surveillance: twice-weekly CTGs and weekly growth scans.\n\n\nAim for delivery at 36–37 weeks if bile acids <100 µmol/L.\n\n\nConsider earlier delivery if bile acids ≥100 µmol/L or evidence of fetal compromise.\n\n\nCounseling Provided:\n\n\nDiscussed nature of obstetric cholestasis and increased risk of stillbirth in twin pregnancies.\n\n\nReassured about ongoing monitoring and early delivery plan.\n\n\nAdvised to monitor fetal movements closely and report any reduction.\n\n\nProvided written information and contact details for triage if symptoms worsen.\n\n\nDictated by: Dr. [Fictional Name] Patel\n Date: [Fictional Date]\n--Note: This is a fictional dictation for testing purposes only. No real patient data or medical advice is contained herein.\n\n\n\nGuideline Analysis:\n### Intrahepatic Cholestasis of Pregnancy: Diagnosis and Management\n\nHere is the analysis of the clinical note against the provided guideline, with recommendations for improvement:\n\n### Very Important Recommendations\n1. **Different management plan** - Avoid routine use of ursodeoxycholic acid (UDCA) unless for symptomatic relief, as it does not improve perinatal outcomes.  \n   Reason: Guideline states \"Do not routinely offer ursodeoxycholic acid for adverse perinatal outcomes in ICP.\"  \n\n2. **Different management plan** - Reduce frequency of CTG monitoring, as it does not predict or prevent stillbirth in ICP.  \n   Reason: Guideline states \"Fetal ultrasound and cardiotocography do not predict or prevent stillbirth in ICP.\"  \n\n3. **Improved patient advice** - Counsel the patient about the higher risk of pre-eclampsia and gestational diabetes, and ensure regular monitoring for these conditions.  \n   Reason: Guideline states \"Women with ICP have a higher chance of developing pre-eclampsia or gestational diabetes. They should have regular monitoring for these conditions.\"  \n\n### Somewhat Important Recommendations  \n1. **Additional information needed** - Document baseline bile acid levels from booking bloods if available, to establish a reference for comparison.  \n   Reason: Guideline recommends baseline measurements in subsequent pregnancies to establish normal levels.  \n\n2. **Different management plan** - Consider discussing with a hepatologist if bile acids are very high or presentation is atypical.  \n   Reason: Guideline states \"Specialist hepatology advice should be sought for severe, very early, or atypical presentations of ICP.\"  \n\n3. **Improved patient advice** - Provide information on long-term risks (hepatobiliary and immune-mediated diseases) and recurrence in future pregnancies.  \n   Reason: Guideline notes increased long-term risks and recurrence likelihood.  \n\n### Less Important Recommendations  \n1. **Additional information needed** - Consider checking vitamin K levels only if steatorrhea or abnormal coagulation is present.  \n   Reason: Guideline states \"routine use of vitamin K treatment is not recommended unless symptoms such as steatorrhoea are present.\"  \n\n2. **Improved patient advice** - Offer links to ICP support groups (e.g., ICP Support, RCOG).  \n   Reason: Guideline provides useful links for patient education.  \n\n### Unimportant Recommendations  \n1. **Different management plan** - Adjust delivery timing slightly if bile acids are borderline (e.g., closer to 36 weeks if near 100 µmol/L).  \n   Reason: Guideline supports individualization but does not specify exact timing for borderline cases.  \n\nThis structured approach ensures critical guideline adherence while optimizing patient care. Would you like any refinements based on specific institutional protocols?\n\n\n## Summary\n\nAnalyzed against the most relevant guideline successfully.\n\n*Note: Found 50 relevant guidelines total, analyzed against the most relevant one.*\n\n\nGuideline: Intrahepatic Cholestasis of Pregnancy: Diagnosis and Management\n\nPlease extract actionable suggestions from this analysis and format them as specified.",
    "system_prompt": "You are a medical AI assistant that converts clinical guideline analysis into structured, actionable suggestions. \n\nYour task is to analyze the provided guideline analysis and extract specific, actionable suggestions that can be presented to the user for acceptance, rejection, or modification.\n\nFor each suggestion you identify, return ONLY a valid JSON object with the following structure:\n{\n  \"suggestions\": [\n    {\n      \"id\": \"1\",\n      \"originalText\": \"text from transcript that needs changing OR description of missing element\",\n      \"suggestedText\": \"proposed replacement text\",\n      \"context\": \"brief explanation of why this change is suggested\",\n      \"category\": \"addition|modification|deletion|formatting\",\n      \"priority\": \"high|medium|low\",\n      \"guidelineReference\": \"specific guideline section or rule\"\n    }\n  ]\n}\n\nCRITICAL FORMATTING REQUIREMENTS:\n- Return ONLY the JSON object - no markdown code blocks, no explanatory text\n- Do not wrap the JSON in ```json or ``` blocks\n- Start your response directly with { and end with }\n- Use sequential numeric IDs starting from \"1\"\n- Ensure all JSON is properly formatted and valid\n\nImportant guidelines for originalText field:\n- For MODIFICATIONS: Use the exact text from the transcript that needs to be changed\n- For ADDITIONS (missing elements): Use descriptive text like \"Missing: cervical length screening documentation\" or \"Gap: no discussion of antenatal corticosteroids\"\n- DO NOT use phrases like \"no additional cervical length screening ordered\" unless those exact words appear in the transcript\n- For missing elements, be clear that you're identifying an absence, not quoting existing text\n\nOther important guidelines:\n- Only suggest changes that are explicitly supported by the guideline analysis\n- Make suggestions specific and actionable\n- For modifications, ensure original text selections are precise and findable in the transcript\n- Keep context explanations concise but informative\n- Prioritize suggestions based on clinical importance\n- If no specific suggestions can be made, return {\"suggestions\": []}",
    "transcript_length": 3421,
    "analysis_length": 2983,
    "guideline_id": "bjog-2022-girling-intrahepatic-cholestasis-of-pregnancy-pdf",
    "guideline_title": "Intrahepatic Cholestasis of Pregnancy: Diagnosis and Management"
  },
  "response": "{\n  \"suggestions\": [\n    {\n      \"id\": \"1\",\n      \"originalText\": \"Start ursodeoxycholic acid 500 mg BID while awaiting results.\",\n      \"suggestedText\": \"Consider ursodeoxycholic acid only for symptomatic relief if needed, not for perinatal outcomes.\",\n      \"context\": \"Guideline recommends against routine UDCA use for perinatal outcomes in ICP\",\n      \"category\": \"modification\",\n      \"priority\": \"high\",\n      \"guidelineReference\": \"Do not routinely offer ursodeoxycholic acid for adverse perinatal outcomes in ICP\"\n    },\n    {\n      \"id\": \"2\",\n      \"originalText\": \"Increase surveillance: twice-weekly CTGs and weekly growth scans.\",\n      \"suggestedText\": \"Reduce CTG monitoring frequency as it doesn't predict stillbirth in ICP\",\n      \"context\": \"Guideline states CTG monitoring doesn't predict or prevent stillbirth in ICP\",\n      \"category\": \"modification\",\n      \"priority\": \"high\",\n      \"guidelineReference\": \"Fetal ultrasound and cardiotocography do not predict or prevent stillbirth in ICP\"\n    },\n    {\n      \"id\": \"3\",\n      \"originalText\": \"Counseling Provided: Discussed nature of obstetric cholestasis and increased risk of stillbirth in twin pregnancies.\",\n      \"suggestedText\": \"Counseling should include risks of pre-eclampsia and gestational diabetes, with monitoring plan\",\n      \"context\": \"Guideline recommends discussing these additional risks and monitoring\",\n      \"category\": \"addition\",\n      \"priority\": \"high\",\n      \"guidelineReference\": \"Women with ICP have higher chance of developing pre-eclampsia or gestational diabetes\"\n    },\n    {\n      \"id\": \"4\",\n      \"originalText\": \"Missing: baseline bile acid levels from booking bloods\",\n      \"suggestedText\": \"Document baseline bile acid levels from booking bloods if available\",\n      \"context\": \"Guideline recommends baseline measurements for comparison\",\n      \"category\": \"addition\",\n      \"priority\": \"medium\",\n      \"guidelineReference\": \"Baseline measurements recommended in subsequent pregnancies\"\n    },\n    {\n      \"id\": \"5\",\n      \"originalText\": \"Missing: hepatology consultation discussion\",\n      \"suggestedText\": \"Consider hepatology consultation if bile acids are very high or presentation atypical\",\n      \"context\": \"Guideline recommends specialist input for severe/atypical cases\",\n      \"category\": \"addition\",\n      \"priority\": \"medium\",\n      \"guidelineReference\": \"Specialist hepatology advice should be sought for severe/atypical presentations\"\n    },\n    {\n      \"id\": \"6\",\n      \"originalText\": \"Counseling Provided: Reassured about ongoing monitoring and early delivery plan.\",\n      \"suggestedText\": \"Include discussion of long-term hepatobiliary risks and recurrence in future pregnancies\",\n      \"context\": \"Guideline notes increased long-term risks and recurrence likelihood\",\n      \"category\": \"addition\",\n      \"priority\": \"medium\",\n      \"guidelineReference\": \"Guideline notes increased long-term risks and recurrence likelihood\"\n    },\n    {\n      \"id\": \"7\",\n      \"originalText\": \"Missing: vitamin K level assessment\",\n      \"suggestedText\": \"Only check vitamin K levels if steatorrhea or abnormal coagulation present\",\n      \"context\": \"Guideline recommends against routine vitamin K treatment\",\n      \"category\": \"modification\",\n      \"priority\": \"low\",\n      \"guidelineReference\": \"Routine use of vitamin K treatment is not recommended unless symptoms present\"\n    },\n    {\n      \"id\": \"8\",\n      \"originalText\": \"Missing: ICP support group information\",\n      \"suggestedText\": \"Offer links to ICP support groups (e.g., ICP Support, RCOG)\",\n      \"context\": \"Guideline provides useful links for patient education\",\n      \"category\": \"addition\",\n      \"priority\": \"low\",\n      \"guidelineReference\": \"Guideline provides useful links for patient education\"\n    }\n  ]\n}",
  "endpoint": "dynamicAdvice",
  "timestamp": "2025-06-13T16-52-41",
  "textContent": "AI: DeepSeek (deepseek-chat)\n\nQ: {\n  \"prompt\": \"Original Transcript:\\nDictation: Clinical Interaction – Twin Pregnancy with Obstetric Cholestasis\\n Patient Details:\\nName: [Fictional Name] Sarah Ahmed\\n\\n\\nAge: 32\\n\\n\\nBMI: 24.7 (weight 68 kg, height 1.66 m)\\n\\n\\nGravida: 2, Para: 1 (previous spontaneous vaginal delivery at term)\\n\\n\\nCurrent Gestation: 32+2 weeks (DCDA twins confirmed on early scan)\\n\\n\\nBooking bloods and anomaly scans: Unremarkable\\n\\n\\nHistory of Presenting Complaint:\\n Ms. Ahmed presents with a 10-day history of worsening pruritus, predominantly affecting her palms and soles, with associated sleep disturbance. She denies any new skin rashes or recent medication changes. No history of abdominal pain, dark urine, or pale stools. Fetal movements are reported as normal for both twins. No vaginal bleeding or uterine tightenings.\\nRelevant Obstetric History:\\nPrevious pregnancy uncomplicated; term vaginal delivery.\\n\\n\\nNo history of intrahepatic cholestasis in prior pregnancy.\\n\\n\\nNo history of preterm labour or hypertensive disorders.\\n\\n\\nRelevant Medical History:\\nMild childhood asthma (not on regular treatment).\\n\\n\\nNo known liver or gallbladder disease.\\n\\n\\nMedications & Allergies:\\nCurrently taking ferrous fumarate and pregnancy multivitamin.\\n\\n\\nNo known drug allergies.\\n\\n\\nSocial History:\\nLives with husband and toddler son.\\n\\n\\nNon-smoker; does not consume alcohol.\\n\\n\\nWorks part-time as a dental nurse; currently on maternity leave.\\n\\n\\nExamination Findings:\\nGeneral: Alert and well, no jaundice noted.\\n\\n\\nAbdomen: Uterus consistent with gestational age; fundal height 33 cm.\\n\\n\\nTwins in cephalic/cephalic lie; both heartbeats auscultated and regular.\\n\\n\\nNo uterine tenderness or signs of labour.\\n\\n\\nNo peripheral oedema; BP 118/74 mmHg.\\n\\n\\nNotable Omissions (for testing purposes):\\nNo documented baseline bile acid levels from booking bloods.\\n\\n\\nNo record of fetal growth scan within the last 2 weeks.\\n\\n\\nNo documentation of CTG to assess current fetal wellbeing.\\n\\n\\nImpression:\\n Twin pregnancy (DCDA) complicated by suspected obstetric cholestasis. Pruritus in the absence of rash raises concern for intrahepatic cholestasis of pregnancy (ICP), particularly given gestation and multifetal pregnancy.\\nManagement Plan:\\nInvestigations:\\n\\n\\nSerum bile acids and liver function tests (LFTs) urgently.\\n\\n\\nFasting bile acids if initial results are borderline.\\n\\n\\nFull blood count and clotting screen (due to potential risk of coagulopathy).\\n\\n\\nCTG to assess fetal wellbeing.\\n\\n\\nGrowth scan and umbilical artery Dopplers if not done in past 2 weeks.\\n\\n\\nMedical Management:\\n\\n\\nStart ursodeoxycholic acid 500 mg BID while awaiting results.\\n\\n\\nConsider chlorphenamine for symptomatic relief of itching.\\n\\n\\nOngoing Care and Delivery Planning:\\n\\n\\nWeekly bile acids and LFTs.\\n\\n\\nIncrease surveillance: twice-weekly CTGs and weekly growth scans.\\n\\n\\nAim for delivery at 36–37 weeks if bile acids <100 µmol/L.\\n\\n\\nConsider earlier delivery if bile acids ≥100 µmol/L or evidence of fetal compromise.\\n\\n\\nCounseling Provided:\\n\\n\\nDiscussed nature of obstetric cholestasis and increased risk of stillbirth in twin pregnancies.\\n\\n\\nReassured about ongoing monitoring and early delivery plan.\\n\\n\\nAdvised to monitor fetal movements closely and report any reduction.\\n\\n\\nProvided written information and contact details for triage if symptoms worsen.\\n\\n\\nDictated by: Dr. [Fictional Name] Patel\\n Date: [Fictional Date]\\n--Note: This is a fictional dictation for testing purposes only. No real patient data or medical advice is contained herein.\\n\\n\\n\\nGuideline Analysis:\\n### Intrahepatic Cholestasis of Pregnancy: Diagnosis and Management\\n\\nHere is the analysis of the clinical note against the provided guideline, with recommendations for improvement:\\n\\n### Very Important Recommendations\\n1. **Different management plan** - Avoid routine use of ursodeoxycholic acid (UDCA) unless for symptomatic relief, as it does not improve perinatal outcomes.  \\n   Reason: Guideline states \\\"Do not routinely offer ursodeoxycholic acid for adverse perinatal outcomes in ICP.\\\"  \\n\\n2. **Different management plan** - Reduce frequency of CTG monitoring, as it does not predict or prevent stillbirth in ICP.  \\n   Reason: Guideline states \\\"Fetal ultrasound and cardiotocography do not predict or prevent stillbirth in ICP.\\\"  \\n\\n3. **Improved patient advice** - Counsel the patient about the higher risk of pre-eclampsia and gestational diabetes, and ensure regular monitoring for these conditions.  \\n   Reason: Guideline states \\\"Women with ICP have a higher chance of developing pre-eclampsia or gestational diabetes. They should have regular monitoring for these conditions.\\\"  \\n\\n### Somewhat Important Recommendations  \\n1. **Additional information needed** - Document baseline bile acid levels from booking bloods if available, to establish a reference for comparison.  \\n   Reason: Guideline recommends baseline measurements in subsequent pregnancies to establish normal levels.  \\n\\n2. **Different management plan** - Consider discussing with a hepatologist if bile acids are very high or presentation is atypical.  \\n   Reason: Guideline states \\\"Specialist hepatology advice should be sought for severe, very early, or atypical presentations of ICP.\\\"  \\n\\n3. **Improved patient advice** - Provide information on long-term risks (hepatobiliary and immune-mediated diseases) and recurrence in future pregnancies.  \\n   Reason: Guideline notes increased long-term risks and recurrence likelihood.  \\n\\n### Less Important Recommendations  \\n1. **Additional information needed** - Consider checking vitamin K levels only if steatorrhea or abnormal coagulation is present.  \\n   Reason: Guideline states \\\"routine use of vitamin K treatment is not recommended unless symptoms such as steatorrhoea are present.\\\"  \\n\\n2. **Improved patient advice** - Offer links to ICP support groups (e.g., ICP Support, RCOG).  \\n   Reason: Guideline provides useful links for patient education.  \\n\\n### Unimportant Recommendations  \\n1. **Different management plan** - Adjust delivery timing slightly if bile acids are borderline (e.g., closer to 36 weeks if near 100 µmol/L).  \\n   Reason: Guideline supports individualization but does not specify exact timing for borderline cases.  \\n\\nThis structured approach ensures critical guideline adherence while optimizing patient care. Would you like any refinements based on specific institutional protocols?\\n\\n\\n## Summary\\n\\nAnalyzed against the most relevant guideline successfully.\\n\\n*Note: Found 50 relevant guidelines total, analyzed against the most relevant one.*\\n\\n\\nGuideline: Intrahepatic Cholestasis of Pregnancy: Diagnosis and Management\\n\\nPlease extract actionable suggestions from this analysis and format them as specified.\",\n  \"system_prompt\": \"You are a medical AI assistant that converts clinical guideline analysis into structured, actionable suggestions. \\n\\nYour task is to analyze the provided guideline analysis and extract specific, actionable suggestions that can be presented to the user for acceptance, rejection, or modification.\\n\\nFor each suggestion you identify, return ONLY a valid JSON object with the following structure:\\n{\\n  \\\"suggestions\\\": [\\n    {\\n      \\\"id\\\": \\\"1\\\",\\n      \\\"originalText\\\": \\\"text from transcript that needs changing OR description of missing element\\\",\\n      \\\"suggestedText\\\": \\\"proposed replacement text\\\",\\n      \\\"context\\\": \\\"brief explanation of why this change is suggested\\\",\\n      \\\"category\\\": \\\"addition|modification|deletion|formatting\\\",\\n      \\\"priority\\\": \\\"high|medium|low\\\",\\n      \\\"guidelineReference\\\": \\\"specific guideline section or rule\\\"\\n    }\\n  ]\\n}\\n\\nCRITICAL FORMATTING REQUIREMENTS:\\n- Return ONLY the JSON object - no markdown code blocks, no explanatory text\\n- Do not wrap the JSON in ```json or ``` blocks\\n- Start your response directly with { and end with }\\n- Use sequential numeric IDs starting from \\\"1\\\"\\n- Ensure all JSON is properly formatted and valid\\n\\nImportant guidelines for originalText field:\\n- For MODIFICATIONS: Use the exact text from the transcript that needs to be changed\\n- For ADDITIONS (missing elements): Use descriptive text like \\\"Missing: cervical length screening documentation\\\" or \\\"Gap: no discussion of antenatal corticosteroids\\\"\\n- DO NOT use phrases like \\\"no additional cervical length screening ordered\\\" unless those exact words appear in the transcript\\n- For missing elements, be clear that you're identifying an absence, not quoting existing text\\n\\nOther important guidelines:\\n- Only suggest changes that are explicitly supported by the guideline analysis\\n- Make suggestions specific and actionable\\n- For modifications, ensure original text selections are precise and findable in the transcript\\n- Keep context explanations concise but informative\\n- Prioritize suggestions based on clinical importance\\n- If no specific suggestions can be made, return {\\\"suggestions\\\": []}\",\n  \"transcript_length\": 3421,\n  \"analysis_length\": 2983,\n  \"guideline_id\": \"bjog-2022-girling-intrahepatic-cholestasis-of-pregnancy-pdf\",\n  \"guideline_title\": \"Intrahepatic Cholestasis of Pregnancy: Diagnosis and Management\"\n}\n\nA: {\n  \"suggestions\": [\n    {\n      \"id\": \"1\",\n      \"originalText\": \"Start ursodeoxycholic acid 500 mg BID while awaiting results.\",\n      \"suggestedText\": \"Consider ursodeoxycholic acid only for symptomatic relief if needed, not for perinatal outcomes.\",\n      \"context\": \"Guideline recommends against routine UDCA use for perinatal outcomes in ICP\",\n      \"category\": \"modification\",\n      \"priority\": \"high\",\n      \"guidelineReference\": \"Do not routinely offer ursodeoxycholic acid for adverse perinatal outcomes in ICP\"\n    },\n    {\n      \"id\": \"2\",\n      \"originalText\": \"Increase surveillance: twice-weekly CTGs and weekly growth scans.\",\n      \"suggestedText\": \"Reduce CTG monitoring frequency as it doesn't predict stillbirth in ICP\",\n      \"context\": \"Guideline states CTG monitoring doesn't predict or prevent stillbirth in ICP\",\n      \"category\": \"modification\",\n      \"priority\": \"high\",\n      \"guidelineReference\": \"Fetal ultrasound and cardiotocography do not predict or prevent stillbirth in ICP\"\n    },\n    {\n      \"id\": \"3\",\n      \"originalText\": \"Counseling Provided: Discussed nature of obstetric cholestasis and increased risk of stillbirth in twin pregnancies.\",\n      \"suggestedText\": \"Counseling should include risks of pre-eclampsia and gestational diabetes, with monitoring plan\",\n      \"context\": \"Guideline recommends discussing these additional risks and monitoring\",\n      \"category\": \"addition\",\n      \"priority\": \"high\",\n      \"guidelineReference\": \"Women with ICP have higher chance of developing pre-eclampsia or gestational diabetes\"\n    },\n    {\n      \"id\": \"4\",\n      \"originalText\": \"Missing: baseline bile acid levels from booking bloods\",\n      \"suggestedText\": \"Document baseline bile acid levels from booking bloods if available\",\n      \"context\": \"Guideline recommends baseline measurements for comparison\",\n      \"category\": \"addition\",\n      \"priority\": \"medium\",\n      \"guidelineReference\": \"Baseline measurements recommended in subsequent pregnancies\"\n    },\n    {\n      \"id\": \"5\",\n      \"originalText\": \"Missing: hepatology consultation discussion\",\n      \"suggestedText\": \"Consider hepatology consultation if bile acids are very high or presentation atypical\",\n      \"context\": \"Guideline recommends specialist input for severe/atypical cases\",\n      \"category\": \"addition\",\n      \"priority\": \"medium\",\n      \"guidelineReference\": \"Specialist hepatology advice should be sought for severe/atypical presentations\"\n    },\n    {\n      \"id\": \"6\",\n      \"originalText\": \"Counseling Provided: Reassured about ongoing monitoring and early delivery plan.\",\n      \"suggestedText\": \"Include discussion of long-term hepatobiliary risks and recurrence in future pregnancies\",\n      \"context\": \"Guideline notes increased long-term risks and recurrence likelihood\",\n      \"category\": \"addition\",\n      \"priority\": \"medium\",\n      \"guidelineReference\": \"Guideline notes increased long-term risks and recurrence likelihood\"\n    },\n    {\n      \"id\": \"7\",\n      \"originalText\": \"Missing: vitamin K level assessment\",\n      \"suggestedText\": \"Only check vitamin K levels if steatorrhea or abnormal coagulation present\",\n      \"context\": \"Guideline recommends against routine vitamin K treatment\",\n      \"category\": \"modification\",\n      \"priority\": \"low\",\n      \"guidelineReference\": \"Routine use of vitamin K treatment is not recommended unless symptoms present\"\n    },\n    {\n      \"id\": \"8\",\n      \"originalText\": \"Missing: ICP support group information\",\n      \"suggestedText\": \"Offer links to ICP support groups (e.g., ICP Support, RCOG)\",\n      \"context\": \"Guideline provides useful links for patient education\",\n      \"category\": \"addition\",\n      \"priority\": \"low\",\n      \"guidelineReference\": \"Guideline provides useful links for patient education\"\n    }\n  ]\n}\n\n--- Token Usage Report ---\nPrompt tokens: 1771\nCompletion tokens: 851\nTotal tokens: 2622\nEstimated cost: $0.001311",
  "ai_provider": "DeepSeek",
  "ai_model": "deepseek-chat",
  "token_usage": {
    "prompt_tokens": 1771,
    "completion_tokens": 851,
    "total_tokens": 2622,
    "estimated_cost_usd": 0.001311
  }
}